BNTX – BioNTech SE
BioNTech SEBNTX
$106.72Name : BioNTech SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $25,654,956,032.00
EPSttm : -3.72
BioNTech SE
$106.72
0.55%$0.58Float Short %
2.58
Margin Of Safety %
Put/Call OI Ratio
0.92
EPS Next Q Diff
0.99
EPS Last/This Y
-1.2
EPS This/Next Y
-0.44
Price
106.7
Target Price
140.77
Analyst Recom
1.52
Performance Q
11.87
Relative Volume
0.4
Beta
1.29
Ticker: BNTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | BNTX | 113.2 | 0.67 | 0.88 | 57319 |
| 2025-06-03 | BNTX | 115.62 | 0.70 | 0.38 | 59523 |
| 2025-06-04 | BNTX | 111.14 | 0.77 | 0.88 | 58069 |
| 2025-06-05 | BNTX | 110.1 | 0.78 | 0.77 | 59843 |
| 2025-06-06 | BNTX | 108.41 | 0.79 | 3.20 | 59737 |
| 2025-06-09 | BNTX | 108.85 | 0.79 | 0.86 | 59888 |
| 2025-06-10 | BNTX | 106.75 | 0.79 | 1.29 | 61434 |
| 2025-06-11 | BNTX | 105.35 | 0.79 | 1.29 | 61676 |
| 2025-06-12 | BNTX | 104.84 | 0.80 | 0.61 | 61914 |
| 2025-06-13 | BNTX | 106.71 | 0.80 | 0.36 | 61928 |
| 2025-06-16 | BNTX | 106.36 | 0.80 | 0.21 | 62003 |
| 2025-06-17 | BNTX | 104.96 | 0.81 | 0.22 | 61537 |
| 2025-06-18 | BNTX | 104.48 | 0.81 | 0.96 | 61696 |
| 2025-06-20 | BNTX | 106.62 | 0.81 | 0.42 | 61764 |
| 2025-06-23 | BNTX | 103.11 | 0.93 | 1.34 | 38036 |
| 2025-06-24 | BNTX | 105.06 | 0.93 | 0.59 | 38428 |
| 2025-06-25 | BNTX | 104.79 | 0.93 | 1.39 | 38811 |
| 2025-06-26 | BNTX | 106 | 0.93 | 0.79 | 38884 |
| 2025-06-27 | BNTX | 106.82 | 0.92 | 3.94 | 39069 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | BNTX | 113.17 | 23.9 | -2530.2 | -5.44 |
| 2025-06-03 | BNTX | 115.64 | 23.9 | -1378.7 | -5.44 |
| 2025-06-04 | BNTX | 111.04 | 23.9 | -1094.5 | -5.44 |
| 2025-06-05 | BNTX | 110.15 | 39.3 | -1270.3 | -4.56 |
| 2025-06-06 | BNTX | 108.42 | 39.3 | -1245.2 | -4.26 |
| 2025-06-09 | BNTX | 108.97 | 50.4 | -1364.2 | -4.26 |
| 2025-06-10 | BNTX | 106.83 | 50.4 | -1220.1 | -4.29 |
| 2025-06-11 | BNTX | 105.42 | 50.4 | -1258.5 | -4.29 |
| 2025-06-12 | BNTX | 104.92 | 50.4 | -1311.1 | -4.29 |
| 2025-06-13 | BNTX | 106.58 | 39.1 | -1460.5 | -4.89 |
| 2025-06-16 | BNTX | 106.39 | 39.1 | -1337.2 | -4.66 |
| 2025-06-17 | BNTX | 105.01 | 39.1 | -1262.8 | -4.35 |
| 2025-06-18 | BNTX | 104.40 | 39.1 | -1308.9 | -4.35 |
| 2025-06-20 | BNTX | 106.53 | 39.1 | -1449.3 | -4.35 |
| 2025-06-23 | BNTX | 103.00 | 39.1 | -1150.8 | -4.35 |
| 2025-06-24 | BNTX | 105.15 | 39.1 | -1466.9 | -4.35 |
| 2025-06-25 | BNTX | 104.74 | 39.1 | -1355.4 | -4.35 |
| 2025-06-26 | BNTX | 106.15 | 39.1 | -1462.8 | -4.35 |
| 2025-06-27 | BNTX | 106.70 | 39.1 | -1437.3 | -4.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | BNTX | 0.00 | 1.81 | 2.27 |
| 2025-06-03 | BNTX | 0.00 | 1.81 | 2.27 |
| 2025-06-04 | BNTX | 0.00 | 1.81 | 2.27 |
| 2025-06-05 | BNTX | 0.00 | 1.81 | 2.27 |
| 2025-06-06 | BNTX | 0.00 | 1.81 | 2.27 |
| 2025-06-09 | BNTX | 0.00 | 1.83 | 2.27 |
| 2025-06-10 | BNTX | 0.00 | 1.83 | 2.27 |
| 2025-06-11 | BNTX | 0.00 | 1.83 | 2.20 |
| 2025-06-12 | BNTX | 0.00 | 1.83 | 2.20 |
| 2025-06-13 | BNTX | 0.00 | 1.83 | 2.20 |
| 2025-06-16 | BNTX | 0.00 | 3.60 | 2.20 |
| 2025-06-18 | BNTX | 0.00 | 3.60 | 2.20 |
| 2025-06-20 | BNTX | 0.00 | 3.60 | 2.20 |
| 2025-06-23 | BNTX | 0.00 | 1.81 | 2.20 |
| 2025-06-24 | BNTX | 0.00 | 1.81 | 2.20 |
| 2025-06-25 | BNTX | 0.00 | 1.81 | 2.20 |
| 2025-06-26 | BNTX | 0.00 | 1.81 | 2.58 |
| 2025-06-27 | BNTX | 0.00 | 1.81 | 2.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.82
Avg. EPS Est. Current Quarter
-2.04
Avg. EPS Est. Next Quarter
-0.83
Insider Transactions
Institutional Transactions
1.81
Beta
1.29
Average Sales Estimate Current Quarter
147
Average Sales Estimate Next Quarter
724
Fair Value
Quality Score
58
Growth Score
36
Sentiment Score
67
Actual DrawDown %
77
Max Drawdown 5-Year %
-82.2
Target Price
140.77
P/E
Forward P/E
PEG
P/S
8.64
P/B
1.25
P/Free Cash Flow
EPS
-3.44
Average EPS Est. Cur. Y
-4.35
EPS Next Y. (Est.)
-4.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-27.39
Relative Volume
0.4
Return on Equity vs Sector %
-28
Return on Equity vs Industry %
-10.1
EPS 1 7Days Diff
EPS 1 30Days Diff
1
EBIT Estimation
-1437.3
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading